Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology
Company plans to initiate enrollment in a Phase 1b clinical trial in sickle…

Click here to view the original article.